---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008448"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:38:10.048369+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences reports FY2022 net loss $46.2M, cash $79.1M; pipeline updates

## Summary
- Net loss $46.2M for FY2022 vs $42.3M in 2021; R&D expenses $35.2M, G&A $12.1M.
- Cash, equivalents and investments $79.1M as of Dec 31, 2022; additional $53.6M private placement closed Feb 2023.
- CAHmelia-203 in adult classic CAH surpassed 50% enrollment; topline data expected H2 2023.
- Strategic partnership with Kaken Pharmaceutical for tildacerfont in Japan; $15M upfront received; cash runway into 1H 2025.

## SEC filing metadata
- accession: 0000950170-23-008448
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017023008448/0000950170-23-008448-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017023008448/sprb-20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008448
- JSON: https://secwatch.observer/filing/0000950170-23-008448.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008448.txt

## Key facts
- Earnings Releases
  SPRUCE BIOSCIENCES, INC. reported the year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $46.2 million compared to $42.3 million in 2021..
  - Period: the year ended December 31, 2022
  - Net income: Net loss for the year ended December 31, 2022 was $46.2 million compared to $42.3 million in 2021.
  - Result: reported results
  source text: Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the full year ended December 31, 2022 and providing corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1683553/000095017023008448/0000950170-23-008448-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.